Review

Bap1-mediated deubiquitination determines immune tolerance and anti-tumor immunity via modulating eTreg cell differentiation and ferroptosis.

Hai-Yan Liu Yan-Hong Su Danni Chen Boxiao He Ning Yuan Qianhao Wang Bao-Jun Zhang Zhaozu Feng Xiao-Ran Zhang Yifan Yao Lei Lei Anjun Jiao Yi-Lei Zhang Bao-Jun Zhang

Aug 2026 · Cell Death and Differentiation · 0 citations · 93 references

Medicine

TL;DR

This work identifies the histone deubiquitinating enzyme Bap1 as a pivotal regulator of eTreg cell fate via its H2A deubiquitination activity to maintain immune tolerance and restrains antitumor immunity.

DOI PubMed Semantic Scholar

View source

Similar papers

Open access Sep 2026

Glycolytic Reprogramming Mediated by the OTUD4-FXR1-HIF1A Axis Drives Gastric Cancer Progression

Ubiquitination and deubiquitination play critical roles in gastric cancer progression, yet systematic investigations of ubiquitin-regulating proteins in gastric cancer (GC) remain limited. To identify key regulators, we performed Ubiquitin-Focused CRISPR-Cas9 growth-based screening in GC cells and identified the deubiq...

Fu-Lin Wang, Yu Shao, Xiao-Mei Zhuang et al. · International Journal on Bio... · 0 citations

Open access Oct 2026

Chronic XBP1s-mediated activation of the unfolded protein response impairs CD8+ T cell anti-tumor immunity

CD8 + T cells play a crucial role in anti-tumor immunity; however, their functionality is compromised by exhaustion driven by chronic antigen exposure, poor tumor microenvironment, and metabolic dysfunction. Activated CD8 + T cells undergo extensive proteomic remodeling, which includes the induction of the IRE1-X...

Keith A. Nair, Jessica Lee, Olivia Zaleski et al. · Frontiers in Immunology · 0 citations

Sep 2026

Targeting the PRMT5-CBX8 axis overcomes dual barriers of CD8⁺ T cell exclusion and tumor stemness for sensitizing TNBC to anti-PD-1 therapy.

A novel epigenetic pathway orchestrated by PRMT5 that converges on the functional modulation of CBX8 to synchronously governs CD8⁺ T cell exclusion and tumor stemness is unveiled, nominating PRMT5 inhibition as a compelling therapeutic strategy for combination immunotherapy in TNBC.

Cong-Cong Chen, Yu-Heng Zhang, Chang Liu et al. · Oncogene · 0 citations

Aug 2026

CD276 promotes lipid metabolic reprogramming and regulates ferroptosis in clear cell renal cell carcinoma by upregulating FASN expression via SREBP1

The pivotal role of the CD276–SREBP1–FASN axis in regulating lipid metabolism and ferroptosis in ccRCC is revealed, providing a theoretical basis for CD276-targeted therapy combined with ferroptosis induction as a treatment strategy for ccRCC.

Zhi-Yu Zhang, Fan Zhang, Yanhang Yu et al. · Human Cell · 0 citations

Aug 2026

Adaptor AP4M1 promotes hepatocellular carcinoma progression by inhibiting ferroptosis through USP15-mediated deubiquitination and MINK1-dependent phosphorylation.

It is shown that AP4M1 is markedly upregulated in HCC, correlates with unfavorable prognosis, and is functionally involved in driving HCC progression, providing a critical theoretical basis for AP4M1-targeted therapeutic strategies in HCC.

Yuan-Hao Peng, K. Kang, Xuanxuan Li et al. · Cancer Letters · 0 citations

Open access Sep 2026

A microbial chromatin remodeler drives gastric cancer progression and immune evasion by reprogramming the host epigenome.

First-line treatment for gastric cancer (GC) includes PD-1 blockade with chemotherapy, but resistance challenges treatment success. We identify Streptococcus anginosus (SA) as a tumor-resident oncobacterium driving GC progression and immune evasion. SA is enriched in GC patient tumors and drives tumor growth in mice. S...

Xiao-Shan Xie, Yue Wei, Jia-Ying Zheng et al. · Cell Host and Microbe · 0 citations